SCHEMBL290633

SCHEMBL290633

CC(N)Cc1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.57
TAAR1 Q96RJ0 2/20 0.57
CYP2A6 P11509 2/20 0.57
MAOA P21397 1/20 0.57
SLC6A4 P31645 1/20 0.57
SLC6A3 Q01959 1/20 0.57
SIGMAR1 Q99720 1/20 0.57
ADORA2A P29274 1/20 0.57
ADORA1 P30542 1/20 0.57
CHRNA7 P36544 1/20 0.52
FDPS P14324 1/20 0.51
CHRNB2 P17787 3/20 0.50
CHRNA4 P43681 3/20 0.50
PNMT P11086 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
TBXAS1 P24557 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669201 1.00 SLC6A2 (0.57) SLC6A2TAAR1CYP2A6MAOASLC6A4
SCHEMBL12894954 1.00 SLC6A2 (0.57) SLC6A2TAAR1CYP2A6MAOASLC6A4
SCHEMBL4957635 0.85 FDPS (0.46) SLC6A2TAAR1CYP2A6MAOASLC6A4
SCHEMBL13416791 0.85 FDPS (0.49) CYP2A6CHRNA7FDPSCHRNB2CHRNA4
SCHEMBL4741562 0.85 FDPS (0.49) CYP2A6CHRNA7FDPSCHRNB2CHRNA4
SCHEMBL4959182 0.84 FDPS (0.45) SLC6A2TAAR1CYP2A6MAOASLC6A4
SCHEMBL103883 0.83 FDPS (0.55) CHRNA7FDPSCHRNB2CHRNA4CYP1A2
SCHEMBL19079574 0.83 FDPS (0.47) CYP2A6CHRNA7FDPSCHRNB2CHRNA4
SCHEMBL19079571 0.83 FDPS (0.47) CYP2A6CHRNA7FDPSCHRNB2CHRNA4
SCHEMBL19079576 0.83 FDPS (0.47) CYP2A6CHRNA7FDPSCHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 US claimed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 US claimed
EP-3668494-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE Psomagen, Inc. (US) 2020-06-24 EP claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 CN claimed
WO-2019036507-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE uBiome, Inc. (US) 2019-02-21 WO claimed
US-20190050525-A1 RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES PSOMAGEN, INC. 2019-02-14 US claimed
US-12343676-B2 Process and system for capture of carbon dioxide COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2025-07-01 US disclosed
EP-4549384-A2 PROCESS AND SYSTEM FOR CAPTURE OF CARBON DIOXIDE Commonwealth Scientific and Industrial Research Organisation (AU) 2025-05-07 EP disclosed
US-20240382898-A1 PROCESS AND SYSTEM FOR CAPTURE OF CARBON DIOXIDE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2024-11-21 US disclosed
US-12023624-B2 Process and system for capture of carbon dioxide COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2024-07-02 US disclosed
US-20230256381-A1 PROCESS AND SYSTEM FOR CAPTURE OF CARBON DIOXIDE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-08-17 US disclosed
US-11602714-B2 Process and system for capture of carbon dioxide COMMONWEATH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-03-14 US disclosed
CN-113683535-B Compound containing cyanoguanidine structure and preparation method and application thereof 中国药科大学 2022-08-30 CN disclosed
EP-0900207-B1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO INC (US) 2001-11-21 EP disclosed
EP-1129075-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS Novartis AG (CH) 2001-09-05 EP disclosed
WO-2000027820-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2000-05-18 WO disclosed
CN-1222909-A Pyrazinone thrombin inhibitors MERCK & CO INC (US) 1999-07-14 CN disclosed
EP-0900207-A1 PYRAZINONE THROMBIN INHIBITORS Merck & Co., Inc. (US) 1999-03-10 EP disclosed
US-5866573-A Pyrazinone thrombin inhibitors MERCK & CO., INC. (US) 1999-02-02 US disclosed
WO-1997040024-A1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO., INC. (US) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PNMT, MAOA, HNMT SLC6A2 97/4885TAAR1 66/4885CYP2A6 240/4885
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MAOA, PNMT, HNMT SLC6A2 106/4885TAAR1 48/4885CYP2A6 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.